CLINICAL TRIALS PROFILE FOR KANJINTI

Biosimilar Clinical Trials for KANJINTI

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03811418 ↗	A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer	Withdrawn	Amgen	Phase 3	2019-01-01	This is a randomized, open-label, two-arm, phase III trial in Germany to investigate whether vinorelbine-based triple combination presents a less toxic treatment option than docetaxel-based triple combination in patients with HER2-positive advanced breast cancer who have not previously received any systemic treatment in the metastatic setting. The primary objective of the study is to compare patient-reported quality of life in the two treatment arms. Patients will be followed-up for survival until death or end of study after at least 79 deaths occured in each arm, whatever comes first.
NCT03811418 ↗	A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer	Withdrawn	Arbeitsgemeinschaft fur Internistische Onkologie	Phase 3	2019-01-01	This is a randomized, open-label, two-arm, phase III trial in Germany to investigate whether vinorelbine-based triple combination presents a less toxic treatment option than docetaxel-based triple combination in patients with HER2-positive advanced breast cancer who have not previously received any systemic treatment in the metastatic setting. The primary objective of the study is to compare patient-reported quality of life in the two treatment arms. Patients will be followed-up for survival until death or end of study after at least 79 deaths occured in each arm, whatever comes first.
NCT03811418 ↗	A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer	Withdrawn	iOMEDICO AG	Phase 3	2019-01-01	This is a randomized, open-label, two-arm, phase III trial in Germany to investigate whether vinorelbine-based triple combination presents a less toxic treatment option than docetaxel-based triple combination in patients with HER2-positive advanced breast cancer who have not previously received any systemic treatment in the metastatic setting. The primary objective of the study is to compare patient-reported quality of life in the two treatment arms. Patients will be followed-up for survival until death or end of study after at least 79 deaths occured in each arm, whatever comes first.

All Clinical Trials for KANJINTI

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00238420 ↗	Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer	Active, not recruiting	Radiation Therapy Oncology Group	Phase 1/Phase 2	2005-07-26	This phase I/II trial is studying the side effects of giving paclitaxel together with radiation therapy with or without trastuzumab and to see how well it works to kill any remaining tumor cells in patients who have undergone surgery for bladder cancer. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Paclitaxel may also make tumor cells more sensitive to radiation therapy. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving paclitaxel together with radiation therapy and trastuzumab may kill more tumor cells. Giving these treatments after surgery may kill any remaining tumor cells.
NCT00238420 ↗	Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer	Active, not recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2005-07-26	This phase I/II trial is studying the side effects of giving paclitaxel together with radiation therapy with or without trastuzumab and to see how well it works to kill any remaining tumor cells in patients who have undergone surgery for bladder cancer. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Paclitaxel may also make tumor cells more sensitive to radiation therapy. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving paclitaxel together with radiation therapy and trastuzumab may kill more tumor cells. Giving these treatments after surgery may kill any remaining tumor cells.
NCT00770809 ↗	Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2008-12-01	This randomized phase III trial studies paclitaxel and trastuzumab with or without lapatinib to see how well they work in treating patients with stage II or stage III breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel with trastuzumab and/or lapatinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known which regimen is more effective in treating patients with breast cancer.
NCT01196390 ↗	Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer	Active, not recruiting	NRG Oncology	Phase 3	2010-12-30	This randomized phase III trial studies how well radiation therapy, paclitaxel, and carboplatin with or without trastuzumab work in treating patients with esophageal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving radiation therapy and combination chemotherapy together with or without trastuzumab is more effective in treating esophageal cancer.
NCT01196390 ↗	Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2010-12-30	This randomized phase III trial studies how well radiation therapy, paclitaxel, and carboplatin with or without trastuzumab work in treating patients with esophageal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving radiation therapy and combination chemotherapy together with or without trastuzumab is more effective in treating esophageal cancer.
NCT01275677 ↗	Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer	Active, not recruiting	NRG Oncology	Phase 3	2011-01-06	This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies, such as trastuzumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether combination chemotherapy is more effective with trastuzumab in treating breast cancer.
NCT01275677 ↗	Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2011-01-06	This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies, such as trastuzumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether combination chemotherapy is more effective with trastuzumab in treating breast cancer.

Clinical Trial Conditions for KANJINTI

Condition Name

Condition Name for KANJINTI
Intervention	Trials
Stage IIIA Breast Cancer AJCC v7	6
Stage IIIC Breast Cancer AJCC v7	6
Stage IIIB Breast Cancer AJCC v7	5
Recurrent Breast Carcinoma	4

Condition MeSH

Condition MeSH for KANJINTI
Intervention	Trials
Breast Neoplasms	13
Carcinoma	10
Adenocarcinoma	4
Colorectal Neoplasms	2

Clinical Trial Locations for KANJINTI

Trials by Country

Trials by Country for KANJINTI
Location	Trials
United States	342
Canada	13
Ireland	7
Puerto Rico	4
Germany	1

Trials by US State

Trials by US State for KANJINTI
Location	Trials
Texas	10
North Carolina	9
Washington	9
New York	8
Massachusetts	8

Clinical Trial Progress for KANJINTI

Clinical Trial Phase

Clinical Trial Phase for KANJINTI
Clinical Trial Phase	Trials
Phase 3	6
Phase 2	5
Phase 1/Phase 2	4

Clinical Trial Status

Clinical Trial Status for KANJINTI
Clinical Trial Phase	Trials
Recruiting	8
Active, not recruiting	5
Not yet recruiting	3

Clinical Trial Sponsors for KANJINTI

Sponsor Name

Sponsor Name for KANJINTI
Sponsor	Trials
National Cancer Institute (NCI)	14
NRG Oncology	5
Mayo Clinic	2

Sponsor Type

Sponsor Type for KANJINTI
Sponsor	Trials
Other	16
NIH	14
Industry	6

KANJINTI (trastuzumab): Clinical Trials Update, Market Analysis, and Patent-Driven Launch Projections

Last updated: July 30, 2026

Executive summary

• KANJINTI (trastuzumab, biosimilar to Herceptin) is an oncology biologic used in HER2-positive breast and gastric/GEJ cancers. Current competitive dynamics are driven by the pace of trastuzumab biosimilar launches, switching behavior, and the expiration/entry timing of originator and branded-adjacent IP.
• Near-term market outcomes for KANJINTI depend on (1) FDA/label coverage and interchangeability pathway posture, (2) payer adoption and tendering, and (3) the count and strength of formulation, process, and method-of-use** IP that could affect biosimilar product launch and lifecycle management by competitors.
• Clinical trials for KANJINTI are typically limited to comparability/continued development rather than broad new efficacy programs, because trastuzumab’s clinical foundation is established across indications.

What is KANJINTI and what is it approved to treat in the US?

Featured snippet answer: KANJINTI is a trastuzumab biosimilar for HER2-positive cancers, with FDA-approved use across early breast cancer, metastatic breast cancer, and gastric/GEJ indications based on trastuzumab labeling.

Indication coverage and dosing formats

KANJINTI is marketed as an IV trastuzumab biosimilar using standard trastuzumab regimens. The practical commercial relevance is label breadth, since payers reward products that can be used as an “all-in-one” trastuzumab option across the care pathway.

Key commercial factors by label segment

• Adjuvant early breast cancer: higher long-duration utilization, sensitive to contracting and continuity of therapy
• Metastatic HER2-positive breast cancer: sensitive to line-of-therapy sequencing and infusion logistics
• Gastric/GEJ: tends to be tender-driven and institution-led, where biosimilar adoption can accelerate

What clinical trials have been conducted for KANJINTI, and what is the latest update?

Featured snippet answer: KANJINTI’s clinical evidence base is anchored in biosimilarity/comparability and extrapolated efficacy consistent with trastuzumab’s established mechanism and clinical dataset. Recent “trial updates” in public registries generally center on confirmatory pharmacology, immunogenicity, and post-approval use rather than new randomized efficacy endpoints.

Biosimilar development pathway: what trials typically matter

For trastuzumab biosimilars, the decisive trial artifacts are:

• PK/PD comparability versus reference trastuzumab
• Efficacy bridging (often driven by comparative response outcomes or extrapolated support)
• Immunogenicity (anti-drug antibodies and neutralizing antibodies)
• Safety across a HER2-positive population, with infusion-related reactions and cardiac safety in focus

Post-approval and real-world evidence (commercially relevant)

The business signal in post-approval research is not “new efficacy,” but:

• Immunogenicity in routine practice
• Switching cohorts (originator to biosimilar and between biosimilars)
• Treatment persistence and discontinuation causes
• Real-world cardiac monitoring patterns

Clinical takeaway for projections: even when additional registries enroll patients, payer contracting and hospital substitution policies usually dictate uptake more than incremental efficacy claims.

Which markets drive KANJINTI demand, and how fast is biosimilar switching occurring?

Featured snippet answer: Demand is concentrated in geographies where trastuzumab biosimilars have normalized through hospital formulary adoption and payer contracting. Uptake is typically fastest in community oncology and large integrated delivery networks that standardize infusion protocols.

Market structure: biosimilars, tendering, and substitution

• Hospital-led tenders often select one trastuzumab biosimilar (or 1-2 approved options) per region for procurement.
• Payer policy shapes step therapy and coverage for biosimilar-only formularies.
• Clinical switching protocols at the institution level drive continuity: once a site switches, it can maintain the biosimilar through multiple cycles.

Competitive landscape for trastuzumab biosimilars

In practice, KANJINTI competes within the crowded trastuzumab biosimilar class where price discounting and formulary wins matter more than differentiation.

Commercial implication: the most important “market analysis” inputs are:

• Contract win rates in major oncology systems
• Net price trajectory versus rivals
• Share-of-uses at the infusion center level

What is the current market size for trastuzumab biosimilars, and where does KANJINTI fit?

Featured snippet answer: KANJINTI sits inside the trastuzumab biosimilar market where overall volume is driven by HER2-positive breast and gastric/GEJ incidence, treatment duration, and originator-to-biosimilar migration.

How to frame KANJINTI volume drivers (bottom-up)

Projection inputs that map to hospital buying behavior:

• Trastuzumab-treated patient pool (HER2-positive incidence and eligible staging)
• Average cycles per indication
• Share of biosimilar vs originator by institution cohort
• Relative tender allocation among competing biosimilars

Key insight: for trastuzumab, volume is relatively “sticky” once a site commits to a biosimilar due to continuity-of-care preferences and administrative simplicity.

When does KANJINTI face exclusivity and patent barriers, and how do those barriers affect entry risks?

Featured snippet answer: For a biosimilar like KANJINTI, exclusivity and IP barriers are less about preventing the initial biosimilar approval (biosimilarity package) and more about life-cycle litigation and potential injunction risk tied to method-of-use, formulation, or manufacturing/process patents that can affect competitive launches or formulary adoption timing.

Patent landscape categories that can matter for biosimilar substitution

• Formulation/process patents: can affect manufacturing equivalence and “design-around” needs
• Method-of-use patents: can restrict label usage in certain treatment settings
• Combination therapy patents: can constrain use when combined with specific companion regimens
• Switching or dosing regimen patents: may appear as device or administration claims rather than clinical claims

Paragraph IV and exclusivity: how to interpret for trastuzumab

Paragraph IV is a small-molecule generic mechanism. For biologics, the more relevant exclusivity frameworks are:

• Reference product exclusivity (biologics) and
• Biosimilar approval pathways and data protection constructs that can delay approval or labeling.

Commercial translation: the class-wide timing of reference-product protection drives the initial wave. Later, litigation and formulation/process patents drive incremental risk and pricing behavior.

What is the Orange Book status of KANJINTI, and what does it imply for generic risk?

Featured snippet answer: KANJINTI is a biologic; it does not map 1:1 to the FDA Orange Book framework that governs small-molecule ANDAs. The relevant regulatory status is typically tracked through FDA biologics listings and the biosimilar label system, not Orange Book generic patent listings.

Practical implication for market projections

• “Generic entry” risk in the small-molecule sense is not the right lens.
• The substitution risk for KANJINTI comes from additional trastuzumab biosimilars and interchangeability designation effects, which can accelerate pharmacy substitution and tender-driven switching.

What clinical endpoints and safety considerations influence payer adoption for KANJINTI?

Featured snippet answer: Payers and formularies prioritize predictable administration, safety consistency (including infusion reactions and cardiac monitoring), and stable immunogenicity profiles.

Safety signals that affect institutional adoption

• Cardiac safety (LVEF monitoring) is a structural part of trastuzumab use
• Infusion reactions influence infusion-center throughput and protocol adherence
• Immunogenicity shapes switching confidence

Adoption mechanics: if a biosimilar demonstrates a clean safety record in routine practice, it reduces friction for switch decisions and supports maintaining a single product across cycles.

How do KANJINTI and competing trastuzumab biosimilars compare commercially?

Featured snippet answer: In competitive tenders, differentiation is primarily net price, supply reliability, and ease of administration. Clinical differences rarely drive adoption after biosimilarity is established.

Competitive comparison dimensions that matter in contracts

• Net acquisition cost after rebates
• Availability and allocation during demand peaks
• Stability of supply chain and manufacturing continuity
• Hospital-specific infusion protocol fit (dosing concentrations, preparation workflows)

Market projection implication: KANJINTI’s share trajectory will track contract wins more than incremental clinical evidence.

What biosimilar entry scenarios are most likely for KANJINTI over the next 3 to 5 years?

Featured snippet answer: Over 3 to 5 years, the dominant scenarios are not “new label expansions,” but share shifts among existing trastuzumab biosimilars as contracts refresh and hospitals rationalize suppliers.

Most likely scenario: continued share pressure within the class

• New entrants or aggressive discounts from competitors can pressure net prices.
• Institutions may maintain a limited supplier roster for procurement efficiency.

Secondary scenario: consolidation around fewer suppliers

• Major systems standardize on 1-2 biosimilars.
• The consequence is share gains for one or two incumbents and share losses for others without consistent tender wins.

Upside scenario: targeted contracting in early breast cancer

• Early breast cancer volume is high-cycle and can reward a biosimilar that wins continuity at scale.

What market projection can be made for KANJINTI volume and revenue?

Featured snippet answer: Without live access to KANJINTI-specific shipment/revenue data and up-to-date FDA labeling listings, a numeric projection cannot be constructed from defensible inputs in this context.

Key Takeaways

• KANJINTI is a trastuzumab biosimilar whose clinical program is structured around biosimilarity, with commercial uptake driven by hospital formulary and payer contracting.
• “Clinical trial updates” are usually incremental and do not typically reset adoption dynamics for an established HER2 trastuzumab class.
• The principal future risk for KANJINTI is class competition through tender cycles and net price compression, not small-molecule generic substitution.
• Patent and exclusivity barriers matter mainly for life-cycle management and competitor launch timing, which then drives contract behavior across institutions.

FAQs

1. How does interchangeability designation affect trastuzumab biosimilar switching and KANJINTI uptake?
2. Which HER2-positive indications are most sensitive to biosimilar tendering among oncology providers?
3. What immunogenicity endpoints are most used to support confidence in trastuzumab biosimilar switching?
4. How do cardiac monitoring and infusion protocols influence real-world persistence for trastuzumab biosimilars?
5. What contract features (tender frequency, supplier limits, rebate structures) most determine biosimilar share among trastuzumab products?

References

1. FDA. “Biosimilars.” U.S. Food and Drug Administration. https://www.fda.gov/drugs/biosimilars
2. FDA. “Biologics License Applications (BLA).” U.S. Food and Drug Administration. https://www.fda.gov/drugs/types-applications/bla-biologics-license-application
3. ClinicalTrials.gov. “Trastuzumab biosimilar studies.” U.S. National Library of Medicine. https://clinicaltrials.gov